Toxic erythema of chemotherapy presenting at scar and conventional sites: An atypical distribution Authors: Akshay Meena, Tirekha Suyamprakasam Vimala, Bheemanathi Hanuman Srinivas, Sivaranjini Ramassamy Published: 2026 Dear Editor, Toxic erythema of chemotherapy (TEC) typically presents with erythema, edema, and desquamation over acral and intertriginous areas due to drug excretion through sweat glands. Here, we report a case of TEC involving typical sites along with the rare involvement of scar site due to docetaxel, highlighting an unusual presentation of chemotherapy-induced reaction. A 59-year-old female presented with Stage 2 breast invasive ductal carcinoma of the right side, 3 months postradical mastectomy on adjuvant sequential chemotherapy. She has completed three cycles of epirubicin and cyclophosphamide, followed by one cycle of docetaxel. She presented with redness of palms and soles along with painful erosions predominantly involving the body folds, 10 days after the chemotherapy. Cutaneous examination revealed crusted erosions with surrounding erythema involving the cubital fossae, neck, and perianal area and overlying the mastectomy scar site on the chest, along with diffuse tender erythema and peeling of skin over palms and soles [Figure 1]. A single well-defined oral erosion with slough was seen over the hard palate. The rest of the mucocutaneous examination was unremarkable. Tzanck smear and Gram stain from the erosion did not show any abnormality. Histopathological examination from the lesion over the neck revealed a periadnexal inflammatory infiltrate comprising lymphocytes, neutrophils, and few plasma cells and squamous metaplasia of eccrine ducts with necrosis of few ducts [Figure 2]. The above findings were consistent with TEC. The patient was treated with a short course of oral steroids. Substantial improvement was noted at the follow-up consultation 2 weeks later. Clinical images of toxic erythema due to docetaxel. (a) Dull erythema along the margins of the palms and fingers with desquamation. (b) Mastectomy scar-site erythema and crusting. (c) Crusted erosions with background erythema over the neck Microscopy from the lesion on the neck in toxic erythema due to docetaxel. (a) Epidermal degeneration with parakeratosis and neutrophilic aggregates within the epidermis, moderate perivascular and interstitial lymphocytic infiltrates, and eccrine syringosquamous metaplasia (H and E, ×40). (b) the eccrine syringosquamous metaplasia with periadnexal inflammatory infiltrates comprising lymphocytes, neutrophils, and few plasma cells (H and E, ×200) TEC encompasses nonallergic cutaneous reactions to chemotherapeutic agents, including hand–foot syndrome (HFS) and neutrophilic eccrine hidradenitis (NEH). HFS, also known as palmar-plantar erythrodysesthesia, is a specific manifestation of TEC, primarily affecting the palms and soles, mainly due to cytotoxic chemotherapy. Hand–foot skin reaction (HFSR) is a distinct toxicity associated with multikinase inhibitors (MKIs) such as sorafenib, presenting as painful hyperkeratotic plaques, blisters, and callus-like lesions with surrounding erythema involving pressure/friction areas. While HFSR is commonly observed with tyrosine kinase and MKIs, the occurrence of TEC or HFS with taxanes such as docetaxel is distinctly uncommon.[12] In contrast, docetaxel-related flagellate dermatitis/erythema is a recognized but rare cutaneous adverse effect.[3] The proposed pathomechanism that results in TEC is the accumulation of cytotoxic chemotherapeutic agents at sites of eccrine secretion and subsequent damage at sweat glands.[4] In addition, inflammation due to chemotherapy-induced overexpression of cyclooxygenase 2 and capillary damage due to mechanical pressure on the hands and feet have been considered responsible for the symptoms.[5] Clinically, it is characterized by painful erythema and edema of the hands and feet with erosions and superficial ulceration of intertriginous regions. The affected areas may have a dusky appearance and develop bullae with subsequent erosions. It is usually self-limited and resolves with desquamation and postinflammatory hyperpigmentation.[6] The histology includes findings such as vacuolar interface dermatitis, epidermal dysmaturation, or in severe cases, ischemic-type necrosis, along with eccrine squamous syringometaplasia or NEH with perivascular lymphocytic infiltrates that can be sparse or dense and interstitial histiocytes.[7] This is the case of a patient with TEC with the involvement of mastectomy scar site, showing features similar to TEC in addition to traditional sites. The pathophysiology of scar-site involvement in TEC remains poorly understood, as it contradicts the established mechanism of TEC, in which chemotherapeutic agents are excreted through eccrine secretions, leading to sweat gland damage.[3] Since scarring results in the loss of sweat ducts, the possibility of direct tissue damage from chemotherapeutic agents secreted through sweat appears unlikely. Similar to this case, we found only one other report describing TEC involvement at a previous bacillus calmette-guérin (BCG) scar site, along with involvement of typical TEC sites.[8] Chemotherapeutic agents may hinder wound repair, particularly in early scars (2–3 months old), by blocking key pathways. They suppress inflammation, inhibit angiogenesis, and impair cell migration, reducing extracellular matrix production.[9] This altered milieu may make them susceptible to TEC. This case highlights an unusual presentation of TEC with scar-site involvement, with typical microscopic findings, challenging the conventional understanding of its pathophysiology. Although toxic erythema is more commonly associated with tyrosine kinase and MKIs and docetaxel is more frequently reported to cause other cutaneous adverse effects such as flagellate dermatitis, its occurrence with docetaxel remains distinctly uncommon. Recognition of this rare presentation is clinically relevant, as increased awareness during follow-up examinations may facilitate early diagnosis and appropriate management. While eccrine secretion remains the primary mechanism, alternative pathways such as altered vascularity, impaired lymphatic drainage, and direct cytotoxic effects on regenerating tissue may contribute to such atypical presentations. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Conflicts of interest There are no conflicts of interest.